Carl L. Gordon, PhD, CFA has been a member of the Compass board since the company’s inception in 2014. Forbes, for the past six years, has named Carl to its Midas List as one of the top venture capitalists in the world. He is a founding partner, co-head of global private equity, and a member of OrbiMed Advisors LLC (OrbiMed), an investment firm focused on the healthcare sector. Before OrbiMed, Carl was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997, and a fellow at The Rockefeller University from 1993 to 1995.
Carl received a PhD in molecular biology from the Massachusetts Institute of Technology and a BA from Harvard College. He serves on multiple boards of private and publicly traded companies, including Compass Therapeutics, Good Start Genetics, Adimab, Arsanis Biosciences, Passage Bio, Singulex, Alector, Igenica, Armo Biosciences, and ORIC Pharmaceuticals.